BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36379882)

  • 1. Adjuvant cytokine-induced killer cell immunotherapy improves long-term survival in patients with stage I-II non-small cell lung cancer after curative surgery.
    Huang J; Zhao X; Zhang Z; Yang S; Chen X; Shen C; Wang L; Qi Y; Zhang Y
    Cytotherapy; 2023 Feb; 25(2):202-209. PubMed ID: 36379882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy with sequential cytokine-induced killer (CIK) cells in stage IB non-small cell lung cancer.
    Li DP; Li W; Feng J; Chen K; Tao M
    Oncol Res; 2015; 22(2):67-74. PubMed ID: 25706393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of the number and interval of treatment cycles on cytokine-induced killer cells and their adjuvant therapeutic effects in advanced non-small-cell lung cancer (NSCLC).
    Gu Y; Lv H; Zhao J; Li Q; Mu G; Li J; Wuyang J; Lou G; Wang R; Zhang Y; Huang X
    Int Immunopharmacol; 2017 Sep; 50():263-269. PubMed ID: 28711032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
    Lee JH; Lee JH; Lim YS; Yeon JE; Song TJ; Yu SJ; Gwak GY; Kim KM; Kim YJ; Lee JW; Yoon JH
    Gastroenterology; 2015 Jun; 148(7):1383-91.e6. PubMed ID: 25747273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).
    Zhao Y; Qiao G; Wang X; Song Y; Zhou X; Jiang N; Zhou L; Huang H; Zhao J; Morse MA; Hobeika A; Ren J; Lyerly HK
    Clin Transl Oncol; 2019 Jun; 21(6):721-728. PubMed ID: 30374838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study.
    Li R; Wang C; Liu L; Du C; Cao S; Yu J; Wang SE; Hao X; Ren X; Li H
    Cancer Immunol Immunother; 2012 Nov; 61(11):2125-33. PubMed ID: 22581306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
    Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive immunotherapy of cytokine-induced killer cell therapy in the treatment of non-small cell lung cancer.
    Wang M; Cao JX; Pan JH; Liu YS; Xu BL; Li D; Zhang XY; Li JL; Liu JL; Wang HB; Wang ZX
    PLoS One; 2014; 9(11):e112662. PubMed ID: 25412106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the Clinical Efficacy of Dendritic Cell -cytokine Induced Killer Cell-based Adoptive Immunotherapy for Colorectal Cancer.
    Xu H; Qin W; Feng H; Song D; Yang X; Zhang J
    Immunol Invest; 2021 Aug; 50(6):622-633. PubMed ID: 32718264
    [No Abstract]   [Full Text] [Related]  

  • 10. Effectiveness and safety of chemotherapy with cytokine-induced killer cells in non-small cell lung cancer: A systematic review and meta-analysis of 32 randomized controlled trials.
    Xiao Z; Wang CQ; Feng JH; Zhou MH; Wang YZ; Li NN; Sun YP; Liu SY; Yao XS; Li CW; Ma B; Ding J; Chen L
    Cytotherapy; 2019 Feb; 21(2):125-147. PubMed ID: 30554868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous cytokine-induced killer cell therapy in lung cancer patients: a retrospective study.
    Zhang J; Zhu L; Du H; He X; Yin Y; Gu Y; Liu L; Lu K; Guo R; Liu P; Shu Y
    Biomed Pharmacother; 2015 Mar; 70():248-52. PubMed ID: 25776508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term clinical efficacy of cytokine-induced killer cell-based immunotherapy in early-stage esophageal squamous cell carcinoma.
    Liu Y; Zhang Z; Tian Y; Wang D; Liu S; Li L; Hao N; Qin G; Zhao X; Yang S; Huang J; Shen C; Lei Q; Wang L; Zhang Y
    Cytotherapy; 2022 May; 24(5):526-533. PubMed ID: 35219583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models.
    Tao L; Huang G; Shi S; Chen L
    Med Oncol; 2014 Jan; 31(1):777. PubMed ID: 24271420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer.
    Shi SB; Ma TH; Li CH; Tang XY
    Tumori; 2012; 98(3):314-9. PubMed ID: 22825506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of adjuvant cytokine-induced killer cell immunotherapy in patients with colorectal cancer after radical resection.
    Pan QZ; Zhao JJ; Yang CP; Zhou YQ; Lin JZ; Tang Y; Gu JM; Wang QJ; Li YQ; He J; Chen SP; Song MJ; Huang Y; Yang JY; Weng DS; Xia JC
    Oncoimmunology; 2020; 9(1):1752563. PubMed ID: 32363125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
    Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High number of PD-1 positive intratumoural lymphocytes predicts survival benefit of cytokine-induced killer cells for hepatocellular carcinoma patients.
    Chang B; Shen L; Wang K; Jin J; Huang T; Chen Q; Li W; Wu P
    Liver Int; 2018 Aug; 38(8):1449-1458. PubMed ID: 29356308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer.
    Wu C; Jiang J; Shi L; Xu N
    Anticancer Res; 2008; 28(6B):3997-4002. PubMed ID: 19192663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovering single cannabidiol or synergistic antitumor effects of cannabidiol and cytokine-induced killer cells on non-small cell lung cancer cells.
    Li Y; Sharma A; Hoffmann MJ; Skowasch D; Essler M; Weiher H; Schmidt-Wolf IGH
    Front Immunol; 2024; 15():1268652. PubMed ID: 38558822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy and safety of CIK plus radiotherapy for lung cancer: A meta-analysis of 16 randomized controlled trials.
    Xiao Z; Wang CQ; Zhou MH; Li NN; Liu SY; He YJ; Wang YZ; Feng JH; Yao XS; Chen L; Ma B; Yu S; Zeng XT; Li CW; Ding J
    Int Immunopharmacol; 2018 Aug; 61():363-375. PubMed ID: 29945024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.